"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--
"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.
Inhaltsangabe
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville MD PhD and Ashkan Emadi MD PhD Chapter 2. Pharmacogenomics by Molly Graveno PharmD BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy MD Richard F. Little MD and Joshua F. Zeidner MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu PhD Matthew D. Thompson PhD MPH Donna Przepiorka MD PhD and Olanrewaju O. Okusanya Pharm.D. MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi MD PhD and Edward A. Sausville MD PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites Hydroxyurea Asparaginases by Ashkan Emadi MD PhD and Judith E. Karp MD Chapter 7. Antifolate Antimetabolites by Justin Lawson PharmD BCOP Chapter 8. Antimitotics by Edward A. Sausville MD PhD and Ashkan Emadi MD PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair Cell Cycle and Apoptosis by Mira A. Kohorst MD and Scott H. Kaufmann MD PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca MD and Lukasz P. Gondek MD PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai MD PhD and Gabriel Ghiaur MD PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu MD and Ashkan Emadi MD PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton PhD and Katherine H. R. Tkaczuk MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar PhD and Arif Hussain MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples PharmD BCOP and Sagar Lonial MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates Antibody-Drug Conjugates Immunoconjugates and Cytokine-Directed Agents by Alison Duffy PharmD BCOP and Ciera Bernhardi PharmD BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors Vaccines Bispecifics and Engineered T Cells by Mark Yarchoan MD and Elizabeth Jaffee MD Index
List of Contributors Preface PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville MD PhD and Ashkan Emadi MD PhD Chapter 2. Pharmacogenomics by Molly Graveno PharmD BCOP Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy MD Richard F. Little MD and Joshua F. Zeidner MD Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu PhD Matthew D. Thompson PhD MPH Donna Przepiorka MD PhD and Olanrewaju O. Okusanya Pharm.D. MS PART 2. CLASSICAL CYTOTOXIC AGENTS Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi MD PhD and Edward A. Sausville MD PhD Chapter 6. Pyrimidine- and Purine-based Antimetabolites Hydroxyurea Asparaginases by Ashkan Emadi MD PhD and Judith E. Karp MD Chapter 7. Antifolate Antimetabolites by Justin Lawson PharmD BCOP Chapter 8. Antimitotics by Edward A. Sausville MD PhD and Ashkan Emadi MD PhD PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS Chapter 9. Drugs Targeting DNA Repair Cell Cycle and Apoptosis by Mira A. Kohorst MD and Scott H. Kaufmann MD PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca MD and Lukasz P. Gondek MD PhD Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai MD PhD and Gabriel Ghiaur MD PhD PART 4. ORGAN-TARGETED APPROACHES Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu MD and Ashkan Emadi MD PhD Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton PhD and Katherine H. R. Tkaczuk MD Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar PhD and Arif Hussain MD Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples PharmD BCOP and Sagar Lonial MD PART 5. IMMUNE-TARGETED STRATEGIES Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic MD Chapter 17. Monoclonal Antibodies Including Immunoconjugates Antibody-Drug Conjugates Immunoconjugates and Cytokine-Directed Agents by Alison Duffy PharmD BCOP and Ciera Bernhardi PharmD BCOP Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors Vaccines Bispecifics and Engineered T Cells by Mark Yarchoan MD and Elizabeth Jaffee MD Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
